Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma

European Journal of Cancer

Volumn 42, Issue 5, 2006, Pages 646-649

  Gilbertson, Richard J ^b   Langdon, Jaqueline A ^a   Hollander, Andrew ^b   Hernan, Roberto ^b   Hogg, Twala L ^b   Gajjar, Amar ^b   Fuller, Christine ^b   Clifford, Steven C ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

BRAF; Medulloblastoma; PDGFR; RAS

Indexed keywords

B RAF KINASE; H RAS PROTEIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN N RAS; RAS PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CHILD; CHILDHOOD CANCER; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INFANT; MALE; MEDULLOBLASTOMA; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; EXONS; FEMALE; GENES, RAS; HUMANS; INFANT; MALE; MAP KINASE SIGNALING SYSTEM; MEDULLOBLASTOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 33644785805     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.11.023     Document Type: Article

References (24)

1. D.W. Ellison, S.C. Clifford, and A. Gajjar What's new in neurooncology? Recent advances in medulloblastoma Eur J Paediatr Neurol 7 2003 53 66
2. R.J. Gilbertson Medulloblastoma: signalling a change in treatment Lancet Oncol 5 2004 209 218
3. R.J. Gilbertson, and S.C. Clifford PDGFRB is overexpressed in metastatic medulloblastoma Nat Genet 35 2003 197 198
4. T.J. MacDonald, K.M. Brown, and B. LaFleur Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease Nat Genet 29 2001 143 152
5. J. Downward Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22
6. K. Pietras, T. Sjoblom, and K. Rubin PDGF receptors as cancer drug targets Cancer Cell 3 2003 439 443
7. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
8. M.C. Heinrich, C.L. Corless, and A. Duensing PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708 710
9. J. Dancey, and E.A. Sausville Issues and progress with protein kinase inhibitors for cancer treatment Nat Rev Drug Discov 2 2003 296 313
10. G.D. Demetri Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development Hematol Oncol Clin North Am 16 2002 1115 1124
11. C.H. Chang, E.M. Housepian, and C. Herbert Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas Radiology 93 1969 1351 1359
12. P. Kleihues, D.N. Louis, and B.W. Scheithauer The WHO classification of tumors of the nervous system J Neuropathol Exp Neurol 61 2002 215 225
13. A. Gajjar, R. Hernan, and M. Kocak Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma J Clin Oncol 22 2004 984 993
14. A.J. Frank, R. Hernan, and A. Hollander The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma Brain Res Mol Brain Res 121 2004 137 140
15. M. Olivier, R. Eeles, and M. Hollstein The IARC TP53 database: new online mutation analysis and recommendations to users Hum Mutat 19 2002 607 614
16. A. Bardelli, D.W. Parsons, and N. Silliman Mutational analysis of the tyrosine kinome in colorectal cancers Science 300 2003 949
17. R. Dammann, U. Schagdarsurengin, and L. Liu Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma Oncogene 22 2003 3806 3812
18. M.H. Ng, K.M. Lau, and W.S. Wong Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript Brit J Haematol 123 2003 637 645
19. M. van Engeland, G.M. Roemen, and M. Brink K-ras mutations and RASSF1A promoter methylation in colorectal cancer Oncogene 21 2002 3792 3795
20. M. Xing, Y. Cohen, and E. Mambo Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis Cancer Res 64 2004 1664 1668
21. D.H. Kim, J.S. Kim, and J.H. Park Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer Cancer Res 63 2003 6206 6211
22. J. Reifenberger, C.B. Knobbe, and A.A. Sterzinger Frequent alterations of Ras signalling pathway genes in sporadic malignant melanomas Int J Cancer 109 2004 377 384
23. J.C. Lindsey, M.E. Lusher, and J.A. Anderton Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling Carcinogenesis 25 2004 661 668
24. M.E. Lusher, J.C. Lindsey, and F. Latif Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development Cancer Res 62 2002 5906 5911